<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03795363</url>
  </required_header>
  <id_info>
    <org_study_id>18-015669</org_study_id>
    <nct_id>NCT03795363</nct_id>
  </id_info>
  <brief_title>Orkambi Treatment in 2 to 5 Year Old Children With CF</brief_title>
  <official_title>Nutritional Impact of Orkambi Treatment in 2 to 5 Year Old Children Homozygous for F508del Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational research study is to determine the effects of clinically&#xD;
      prescribed Orkambi treatment on 2 to 5 year old children homozygous for the F508del Mutations&#xD;
      in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene on sleeping energy&#xD;
      expenditure, growth status and gut health and function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Orkambi is a novel FDA approved (August, 2018) therapy for use in patients with cystic&#xD;
      fibrosis (CF) who are 2 to 5 years of age and homozygous for F508del mutations in the CFTR&#xD;
      gene. It is a combination of lumacaftor and ivacaftor that addresses both the processing and&#xD;
      gating defects of the F508del mutation. This investigator-initiated study is designed to&#xD;
      evaluate the nutritional, growth and GI impact of Orkambi treatment for this unique younger&#xD;
      (2 to 5 years) patient cohort. This proposal extends previous highly informative nutrition&#xD;
      and weight gain investigation of ivacaftor treatment in people with CF gating mutations to&#xD;
      another CFTR modulator treatment (Orkambi) in people homozygous for F508del mutations. The&#xD;
      primary aims of the study are to evaluate the impact of 24 weeks of Orkambi treatment in 2 to&#xD;
      5 year old subjects with CF homozygous for F508del mutations on sleeping or resting energy&#xD;
      expenditure, growth status and gut health and function in n=32 children ages 2.0 to 5.9 years&#xD;
      of age. Protocol evaluations will occur at baseline (pre-treatment) and 12 and 24 weeks after&#xD;
      clinically prescribed Orkambi treatment has begun. Other outcomes of significant clinical&#xD;
      interest in young subjects with CF will be explored. All subjects will be evaluated as&#xD;
      outpatient at The Children's Hospital of Philadelphia, and will be recruited both regionally&#xD;
      and nationally to ensure timely enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Actual">June 16, 2021</completion_date>
  <primary_completion_date type="Actual">June 16, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sleeping or Resting Energy Expenditure</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine the effects of 24 weeks of orkambi treatment on subject's SEE (sleeping energy expenditure) or REE (resting energy expenditure). Using indirect calorimetry, SEE/REE will be assessed using a computerized metabolic cart Vmax ENCORE at each protocol visit while the child is asleep or resting quietly. SEE/REE will be assessed in the morning if possible and careful note of previous feeding of the child, including the time of day, amount of food, and feeding interval prior to test. It will depend on the age of the subject, and if the subject still takes daily naps and is able to rest quietly without moving, if they will perform sleeping energy expenditure or resting energy expenditure. This will be one outcome measure for each subject, and it will depend on if the subject can nap (SEE) or rest quietly without moving (REE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Assessment</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine the effects of 24 weeks of orkambi treatment on subject's body mass index (BMI). Investigators will compare the results to BMI Z scores over 24 weeks compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal Elastase I/Pancreatic Function</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine the effects of 24 weeks of orkambi treatment on subject's pancreatic function. Pancreatic function will be assessed at two visits by obtaining spot stool samples with fecal elastase 1. The concentration of fecal elastase I is indicative of pancreatic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Calprotectin/Gut Inflammation</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine the effects of 24 weeks of orkambi treatment on subject's fecal calprotectin concentration. Spot stool samples will be obtained to determine fecal calprotectin concentration, which is a marker for gut inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Total Fatty Acids</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine the effects of 24 weeks of orkambi treatment on subject's dietary fat absorption. A total plasma fatty acid panel will be assessed to measure the change in status of 22 fatty acids.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dietary Intake</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Three day weighed food record will be obtained and to determine changes in dietary caloric intake and micro and macronutrient intake over the course of 24 weeks on orkambi treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum fat soluble vitamin levels</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine the changes in serum fat soluble vitamin A, E, D and K concentration levels after 24 weeks of orkambi treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in bile acid concentration levels</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine changes in the concentration levels of 14 bile acid species in subjects over the course of 24 weeks on orkambi treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in concentration levels of serum calprotectin</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will examine changes in the concentration levels of serum calprotectin in subjects over the course of 24 weeks on orkambi treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle-Fat Stores</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will measure body composition to determine muscle and fat store changes over the course of 24 weeks on orkambi treatment compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth status changes</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Investigators will observe the changes in growth status over time. Growth status will be measured by determining the changes in three different measurements- length (cm), weight (kg) and head circumference (cm). Each value will be used to calculate BMI (kg/cm^2), which will be used in accordance with age to determine the growth velocity percentile of the subjects over the course of 24 weeks on orkambi treatment. The growth velocity percentile will be indicative of changes in growth status over time.</description>
  </other_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orkambi</intervention_name>
    <description>Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, stool sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        2 to 5 year old subjects with a diagnosis of cystic fibrosis and homozygous for F508del&#xD;
        mutations and who are in a usual state of good health with a clinical decision to start&#xD;
        orkambi treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cystic fibrosis and homozygous for F508del mutations, approved for treatment&#xD;
&#xD;
          -  Age: 2.0 to 5.9 years&#xD;
&#xD;
          -  In usual state of good health&#xD;
&#xD;
          -  A clinical decision has been made for subject to begin Orkambi treatment&#xD;
&#xD;
          -  Family committed to the 6 to 8 month study protocol with visits to the Children's&#xD;
             Hospital of Philadelphia (CHOP) that will last 2-3 days for the baseline visit (Visit&#xD;
             1) prior to Orkambi and the 24 week visit (Visit 3) after clinically prescribed&#xD;
             Orkambi treatment has begun, and will last up to 2 days for the 12 week visit (Visit&#xD;
             2) after Orkambi treatment has begun.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On parenteral nutrition&#xD;
&#xD;
          -  Use of any medications that inhibit or induce cytochrome P450 (CYP) 3A&#xD;
&#xD;
          -  Liver function tests elevated above 3x the reference range for age and sex&#xD;
&#xD;
          -  Lung disease considered severe based on clinical impression by home CF center.&#xD;
&#xD;
          -  Other illness affecting growth or nutritional status&#xD;
&#xD;
          -  Other contraindications described for Orkambi therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Stallings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations. J Pediatr. 2018 Oct;201:229-237.e4. doi: 10.1016/j.jpeds.2018.05.018. Epub 2018 Jul 18.</citation>
    <PMID>30029855</PMID>
  </reference>
  <reference>
    <citation>Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, Geller DE; VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672.</citation>
    <PMID>22383668</PMID>
  </reference>
  <reference>
    <citation>Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30. doi: 10.1073/pnas.0904709106. Epub 2009 Oct 21.</citation>
    <PMID>19846789</PMID>
  </reference>
  <reference>
    <citation>Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group *. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC.</citation>
    <PMID>27805836</PMID>
  </reference>
  <reference>
    <citation>Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466. No abstract available.</citation>
    <PMID>26510034</PMID>
  </reference>
  <reference>
    <citation>Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser. 1985;724:1-206. No abstract available.</citation>
    <PMID>3937340</PMID>
  </reference>
  <reference>
    <citation>Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr. 1985;39 Suppl 1:5-41.</citation>
    <PMID>4044297</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height, and body mass index-for-age. Geneva, Switzerland: WHO Press, World Health Organization; 2006.</citation>
  </reference>
  <reference>
    <citation>Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J, Jarembek K. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 2004 Sep;145(3):322-6. doi: 10.1016/j.jpeds.2004.04.049.</citation>
    <PMID>15343184</PMID>
  </reference>
  <reference>
    <citation>Borowitz D, Lin R, Baker SS. Comparison of monoclonal and polyclonal ELISAs for fecal elastase in patients with cystic fibrosis and pancreatic insufficiency. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):219-23. doi: 10.1097/MPG.0b013e31802c41de.</citation>
    <PMID>17255835</PMID>
  </reference>
  <reference>
    <citation>O'Connor MG, Seegmiller A. The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study. J Cyst Fibros. 2017 Jan;16(1):132-138. doi: 10.1016/j.jcf.2016.07.006. Epub 2016 Jul 26.</citation>
    <PMID>27473897</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. WHO Child Growth Standards: Head circumference-for-age, arm circumference-for-age, triceps skinfold-for-age, and subscapular skinfold-for-age. Geneva, Switzerland: WHO Press, World Health Organization; 2007.</citation>
  </reference>
  <reference>
    <citation>WHO Multicenter Growth Reference Study Group. WHO Child Growth Standards: Growth Velocity Based on Weight, Length and Head Circumference: Methods and Development. Geneva, Switzerland: WHO Press: World Health Organization; 2009.</citation>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CF</keyword>
  <keyword>CFTR</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03795363/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03795363/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03795363
org study id: 18-015669
nct id: NCT03795363
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
is us export: Yes
The purpose of this observational research study is to determine the effects of clinically
      prescribed Orkambi treatment on 2 to 5 year old children homozygous for the F508del Mutations
      in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene on sleeping energy
      expenditure, growth status and gut health and function.
Orkambi is a novel FDA approved (August, 2018) therapy for use in patients with cystic
      fibrosis (CF) who are 2 to 5 years of age and homozygous for F508del mutations in the CFTR
      gene. It is a combination of lumacaftor and ivacaftor that addresses both the processing and
      gating defects of the F508del mutation. This investigator-initiated study is designed to
      evaluate the nutritional, growth and GI impact of Orkambi treatment for this unique younger
      (2 to 5 years) patient cohort. This proposal extends previous highly informative nutrition
      and weight gain investigation of ivacaftor treatment in people with CF gating mutations to
      another CFTR modulator treatment (Orkambi) in people homozygous for F508del mutations. The
      primary aims of the study are to evaluate the impact of 24 weeks of Orkambi treatment in 2 to
      5 year old subjects with CF homozygous for F508del mutations on sleeping or resting energy
      expenditure, growth status and gut health and function in n=32 children ages 2.0 to 5.9 years
      of age. Protocol evaluations will occur at baseline (pre-treatment) and 12 and 24 weeks after
      clinically prescribed Orkambi treatment has begun. Other outcomes of significant clinical
      interest in young subjects with CF will be explored. All subjects will be evaluated as
      outpatient at The Children's Hospital of Philadelphia, and will be recruited both regionally
      and nationally to ensure timely enrollment.
observational model: Cohort
time perspective: Prospective
measure: Sleeping or Resting Energy Expenditure
time frame: 24 Weeks
description: Investigators will examine the effects of 24 weeks of orkambi treatment on subject's SEE (sleeping energy expenditure) or REE (resting energy expenditure). Using indirect calorimetry, SEE/REE will be assessed using a computerized metabolic cart Vmax ENCORE at each protocol visit while the child is asleep or resting quietly. SEE/REE will be assessed in the morning if possible and careful note of previous feeding of the child, including the time of day, amount of food, and feeding interval prior to test. It will depend on the age of the subject, and if the subject still takes daily naps and is able to rest quietly without moving, if they will perform sleeping energy expenditure or resting energy expenditure. This will be one outcome measure for each subject, and it will depend on if the subject can nap (SEE) or rest quietly without moving (REE).
measure: Anthropometric Assessment
time frame: 24 Weeks
description: Investigators will examine the effects of 24 weeks of orkambi treatment on subject's body mass index (BMI). Investigators will compare the results to BMI Z scores over 24 weeks compared to baseline.
measure: Fecal Elastase I/Pancreatic Function
time frame: 24 Weeks
description: Investigators will examine the effects of 24 weeks of orkambi treatment on subject's pancreatic function. Pancreatic function will be assessed at two visits by obtaining spot stool samples with fecal elastase 1. The concentration of fecal elastase I is indicative of pancreatic function.
measure: Fecal Calprotectin/Gut Inflammation
time frame: 24 Weeks
description: Investigators will examine the effects of 24 weeks of orkambi treatment on subject's fecal calprotectin concentration. Spot stool samples will be obtained to determine fecal calprotectin concentration, which is a marker for gut inflammation.
measure: Plasma Total Fatty Acids
time frame: 24 Weeks
description: Investigators will examine the effects of 24 weeks of orkambi treatment on subject's dietary fat absorption. A total plasma fatty acid panel will be assessed to measure the change in status of 22 fatty acids.
measure: Dietary Intake
time frame: 24 Weeks
description: Three day weighed food record will be obtained and to determine changes in dietary caloric intake and micro and macronutrient intake over the course of 24 weeks on orkambi treatment.
measure: Serum fat soluble vitamin levels
time frame: 24 Weeks
description: Investigators will examine the changes in serum fat soluble vitamin A, E, D and K concentration levels after 24 weeks of orkambi treatment.
measure: Changes in bile acid concentration levels
time frame: 24 Weeks
description: Investigators will examine changes in the concentration levels of 14 bile acid species in subjects over the course of 24 weeks on orkambi treatment.
measure: Changes in concentration levels of serum calprotectin
time frame: 24 Weeks
description: Investigators will examine changes in the concentration levels of serum calprotectin in subjects over the course of 24 weeks on orkambi treatment.
measure: Muscle-Fat Stores
time frame: 24 Weeks
description: Investigators will measure body composition to determine muscle and fat store changes over the course of 24 weeks on orkambi treatment compared to baseline.
measure: Growth status changes
time frame: 24 Weeks
description: Investigators will observe the changes in growth status over time. Growth status will be measured by determining the changes in three different measurements- length (cm), weight (kg) and head circumference (cm). Each value will be used to calculate BMI (kg/cm^2), which will be used in accordance with age to determine the growth velocity percentile of the subjects over the course of 24 weeks on orkambi treatment. The growth velocity percentile will be indicative of changes in growth status over time.
intervention type: Drug
intervention name: Orkambi
description: Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
Blood, stool sample
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 2 Years
maximum age: 5 Years
healthy volunteers: No
last name: Virginia Stallings, MD
role: Principal Investigator
affiliation: Children's Hospital of Philadelphia
facility: 
country: United States
citation: Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations. J Pediatr. 2018 Oct;201:229-237.e4. doi: 10.1016/j.jpeds.2018.05.018. Epub 2018 Jul 18.
PMID: 30029855
citation: Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, Geller DE; VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672.
PMID: 22383668
citation: Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30. doi: 10.1073/pnas.0904709106. Epub 2009 Oct 21.
PMID: 19846789
citation: Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group *. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC.
PMID: 27805836
citation: Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466. No abstract available.
PMID: 26510034
citation: Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser. 1985;724:1-206. No abstract available.
PMID: 3937340
citation: Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr. 1985;39 Suppl 1:5-41.
PMID: 4044297
citation: World Health Organization. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height, and body mass index-for-age. Geneva, Switzerland: WHO Press, World Health Organization; 2006.
citation: Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J, Jarembek K. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 2004 Sep;145(3):322-6. doi: 10.1016/j.jpeds.2004.04.049.
PMID: 15343184
citation: Borowitz D, Lin R, Baker SS. Comparison of monoclonal and polyclonal ELISAs for fecal elastase in patients with cystic fibrosis and pancreatic insufficiency. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):219-23. doi: 10.1097/MPG.0b013e31802c41de.
PMID: 17255835
citation: O'Connor MG, Seegmiller A. The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study. J Cyst Fibros. 2017 Jan;16(1):132-138. doi: 10.1016/j.jcf.2016.07.006. Epub 2016 Jul 26.
PMID: 27473897
citation: World Health Organization. WHO Child Growth Standards: Head circumference-for-age, arm circumference-for-age, triceps skinfold-for-age, and subscapular skinfold-for-age. Geneva, Switzerland: WHO Press, World Health Organization; 2007.
citation: WHO Multicenter Growth Reference Study Group. WHO Child Growth Standards: Growth Velocity Based on Weight, Length and Head Circumference: Methods and Development. Geneva, Switzerland: WHO Press: World Health Organization; 2009.
responsible party type: Sponsor
mesh term: Cystic Fibrosis
mesh term: Fibrosis
provided document: 
provided document: 